Review
Open access
Jul 2026
CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions
The approval of lifileucel in 2024 marked an important milestone in oncology as the first cellular therapy authorized for a solid tumor. This milestone stands in sharp contrast to the success of CAR-T cells in hematologic malignancies, where six products have been licensed, and highlights the central challenge that sol...
Duc-Hiep Bach, Van T. Hoang, T. Pham et al.
· Cancer Cell International · 1 citation